Endocrine Carcinoma — Trials

Endocrine Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

1,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 574
Recruiting: 291
Ph III recruiting: 33
Growth YoY: +1.5%
Industry share: 34%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (236)

clinicaltrialsPublishedShowing 1–17 of 17 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07833839	ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma	not yet recruiting	Phase 3	440	Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY	1	Sep 22, 2026	clinicaltrials
NCT07802821	A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer	not yet recruiting	Phase 3	556	Qilu Pharmaceutical Co., Ltd.INDUSTRY